Hoth Therapeutics (HOTH) said Tuesday that its Alzheimer's drug, HT-ALZ, showed positive preclinical results by significantly lowering astrocyte activity in key brain areas of Alzheimer's model mice, potentially improving cognitive function.
The company said it plans to continue advancing HT-ALZ through additional studies and clinical trials.
It said it is currently conducting a secondary analysis to see if treatment affects the size or total number of astrocytes.
Shares of the company were up nearly 17% in recent Tuesday premarket activity.
Price: 1.1800, Change: +0.17, Percent Change: +16.83
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。